SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2021-08-31** | Period of Report: **2021-08-31** | SEC Accession No. 0001493152-21-021692

(HTML Version on secdatabase.com)

FILER

INTERPACE BIOSCIENCES, INC.

CIK:1054102| IRS No.: 222919486 | State of Incorp.:DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 000-24249 | Film No.: 211227529

SIC: 3841 Surgical & medical instruments & apparatus

Mailing Address MORRIS CORPORATE CENTER 1, BUILDING C, 300 INTERPACE PARKWAY PARSIPPANY NJ 07054 Business Address MORRIS CORPORATE CENTER 1, BUILDING C, 300 INTERPACE PARKWAY PARSIPPANY NJ 07054 412-224-6100

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 31, 2021

INTERPACE BIOSCIENCES, INC.

(Exact name of Registrant as specified in its charter)

DELAWARE
(State or other jurisdiction
of incorporation)

0-24249 (Commission File Number) 22-2919486 (IRS Employer Identification No.)

Morris Corporate Center 1, Building C 300 Interpace Parkway, Parsippany, NJ 07054

(Address, including zip code, of Principal Executive Offices)

(855) 776-6419

Registrant's telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)			
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)			
	Pre-commencement communications pursuant to I	Rule 14d-2(b) under the Exch	nange Act (17 CFR 240.14d-2(b))	
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))			
Securities registered pursuant to Section 12(b) of the Act:				
Title of each class		Trading Symbol(s)	Name of each exchange on which registered	
N/A		N/A	N/A	

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the e	extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the	e Exchange Act. □

Item 1.01. Amendment to Material Definitive Agreement

On January 7, 2021, Interpace Biosciences, Inc. (the "Company") entered into promissory notes with Ampersand 2018 Limited Partnership ("Ampersand"), in the amount of \$3 million (the "Ampersand Note"), and 1315 Capital II, L.P. ("1315 Capital"), in the amount of \$2 million, (the "1315 Capital Note"), respectively (together, the "Notes"), and a related security agreement (the "Security Agreement"). On May 10, 2021, the Company amended the Ampersand Note to increase the principal amount to \$4.5 million, and amended the 1315 Capital Note to increase the principal amount to \$3.0 million. The maturity dates of the Notes were the earlier of (a) June 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Notes.

On June 24, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) August 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On June 25, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner.

On August 31, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) September 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On August 31, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. Except with respect to their respective maturity dates, the terms of the Notes are otherwise unchanged. The Security Agreement remains in full force and effect, and was not amended in connection with the amendments to the Notes.

Ampersand holds 28,000 shares of the Company's Series B Convertible Preferred Stock ("Series B"), which are convertible from time to time into an aggregate of 4,666,666 shares of the Company's Common Stock, and 1315 Capital holds 19,000 shares of the Company's Series B, which are convertible from time to time into an aggregate of 3,166,668 shares of the Company's Common Stock. On an asconverted basis, such shares would represent approximately 38.9% and 26.4% of our fully-diluted shares of Common Stock, respectively. As a result, the Company considers the August 31, 2021 amendments to the Notes to be related party transactions.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Third Amendment to the Ampersand Note, dated August 31, 2021
99.2	Third Amendment to the 1315 Capital Note, dated August 31, 2021
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).
	•

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Interpace Biosciences, Inc.

By: /s/ Thomas W. Burnell

Name: Thomas W. Burnell

Title: President and Chief Executive Officer

Date: August 31, 2021

THIRD AMENDMENT TO SECURED PROMISSORY NOTE

This Third Amendment to Secured Promissory Note (this "Amendment") is made and entered into as of August 31, 2021 (the "Amendment Effective Date") by and between Interpace Biosciences, Inc., a Delaware corporation (the "Borrower"), and Ampersand 2018 Limited Partnership, a Delaware limited partnership (the "Noteholder"). Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Note (as defined below).

WHEREAS, the Borrower has entered into that certain Secured Promissory Note dated as of January 7, 2021 (the "**Note**"), made in favor of the Noteholder, in the aggregate principal amount of \$3,000,000.00;

WHEREAS, the Borrower and the Noteholder on May 10, 2021 amended the Note to increase its aggregate principal amount to \$4,500,000.00;

WHEREAS, the Borrower and Noteholder on June 24, 2021 amended the Note to change its Maturity Date to August 31, 2021;

WHEREAS, pursuant to Section 12.11 of the Note, any term of the Note may be amended or modified with the written consent of the Borrower and the Noteholder; and

WHEREAS, the Borrower and Noteholder desire to amend the Note to change its Maturity Date to September 30, 2021.

NOW, THEREFORE, in accordance with the foregoing and intending to be legally bound hereby, the Borrower and the Noteholder hereby amend the Note as provided for below, and otherwise further agree as follows:

- 1. Amendment to the Note. The Note is hereby amended as follows:
 - (a) The defined term "Maturity Date" is hereby amended and restated in its entirety as follows:

"Maturity Date" means the earlier of (a) September 30, 2021 and (b) the date on which all amounts under this Note shall become due and payable pursuant to Section 11.

- (b) The defined term "Pari Passu Note" is hereby amended and restated in its entirety as follows:
- "Pari Passu Note" means that certain Secured Promissory Note dated January 7, 2021, as amended by that certain Amendment to Secured Promissory Note dated as of May 10, 2021, as further Amended by that certain Second Amendment to Secured Promissory Note dated as of June 25, 2021, as further Amended by that certain Third Amendment to Secured Promissory Note dated as of August 31, 2021, in the principal amount of \$3,000,000.
- 2. <u>Continued Effectiveness</u>. Except as amended hereby, the Note shall remain in full force and effect and all of the rights and obligations under the Note are hereby affirmed. In the event of a conflict between the Note and this Amendment, this Amendment shall control.
- 3. <u>References</u>. From and after the Amendment Effective Date, any reference to the Note contained in any notice, request, certificate or other instrument, document or agreement executed concurrently with or after the execution and delivery of this Amendment shall be deemed to include this Amendment unless the context shall so otherwise require.
- 4. <u>Counterparts</u>. This Amendment may be signed in two or more counterparts (including by means of telecopied signature pages) any one of which need not contain the signature of more than one party, but all such counterparts taken together shall constitute one and the same agreement.

[remainder of page intentionally left blank]

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the date first above written.

INTERPACE BIOSCIENCES, INC.

By: /s/ Thomas W. Burnell

Name: Thomas W. Burnell Title: President and CEO

Ampersand 2018 Limited Partnership By: AMP-18 Management Company Limited Partnership, its General Partner By: AMP-18 MC LLC, its General Partner

By: /s/ Herbert H. Hooper

Name: Herbert H. Hooper Title: Managing Member

[Signature Page to Amendment to Secured Promissory Note]

THIRD AMENDMENT TO SECURED PROMISSORY NOTE

This Third Amendment to Secured Promissory Note (this "Amendment") is made and entered into as of August 31, 2021 (the "Amendment Effective Date") by and between Interpace Biosciences, Inc., a Delaware corporation (the "Borrower"), and 1315 Capital II, L.P., a Delaware limited partnership (the "Noteholder"). Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Note (as defined below).

WHEREAS, the Borrower has entered into that certain Secured Promissory Note dated as of January 7, 2021 (the "**Note**"), made in favor of the Noteholder, in the aggregate principal amount of \$2,000,000.00;

WHEREAS, the Borrower and the Noteholder on May 10, 2021 amended the Note to increase its aggregate principal amount to \$3,000,000.00;

WHEREAS, the Borrower and Noteholder on June 25, 2021 amended the Note to change its Maturity Date to August 31, 2021;

WHEREAS, pursuant to Section 12.11 of the Note, any term of the Note may be amended or modified with the written consent of the Borrower and the Noteholder; and

WHEREAS, the Borrower and Noteholder desire to amend the Note to change its Maturity Date to September 30, 2021.

NOW, THEREFORE, in accordance with the foregoing and intending to be legally bound hereby, the Borrower and the Noteholder hereby amend the Note as provided for below, and otherwise further agree as follows:

- 1. Amendment to the Note. The Note is hereby amended as follows:
 - (a) The defined term "Maturity Date" is hereby amended and restated in its entirety as follows:

"Maturity Date" means the earlier of (a) September 30, 2021 and (b) the date on which all amounts under this Note shall become due and payable pursuant to Section 11.

- (b) The defined term "Pari Passu Note" is hereby amended and restated in its entirety as follows:
- "Pari Passu Note" means that certain Secured Promissory Note dated January 7, 2021, as amended by that certain Amendment to Secured Promissory Note dated as of May 10, 2021, as further Amended by that certain Second Amendment to Secured Promissory Note dated as of June 24, 2021, as further Amended by that certain Third Amendment to Secured Promissory Note dated as of August 31, 2021, in the principal amount of \$4,500,000.
- 2. <u>Continued Effectiveness</u>. Except as amended hereby, the Note shall remain in full force and effect and all of the rights and obligations under the Note are hereby affirmed. In the event of a conflict between the Note and this Amendment, this Amendment shall control.
- 3. <u>References</u>. From and after the Amendment Effective Date, any reference to the Note contained in any notice, request, certificate or other instrument, document or agreement executed concurrently with or after the execution and delivery of this Amendment shall be deemed to include this Amendment unless the context shall so otherwise require.
- 4. <u>Counterparts</u>. This Amendment may be signed in two or more counterparts (including by means of telecopied signature pages) any one of which need not contain the signature of more than one party, but all such counterparts taken together shall constitute one and the same agreement.

[remainder of page intentionally left blank]

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the date first above written.

INTERPACE BIOSCIENCES, INC.

By: /s/ Thomas W. Burnell

Name: Thomas W. Burnell Title: President and CEO

1315 CAPITAL II, L.P. By: 1315 Capital Management II, LLC,

its general partner

By: /s/ Adele C. Olvia Name: Adele C. Oliva

Title: Managing Member

[Signature Page to Amendment to Secured Promissory Note]

3

Cover Aug. 31, 2021

Cover [Abstract]

Document Type 8-K
Amendment Flag false

Document Period End Date
Aug. 31, 2021
Entity File Number
0-24249

Entity Registrant Name INTERPACE Biosciences, INC.

Entity Central Index Key0001054102Entity Tax Identification Number22-2919486

Entity Incorporation, State or Country Code DE

Entity Address, Address Line One Morris Corporate Center 1

Entity Address, Address Line Two

Building C

Entity Address, Address Line Three 300 Interpace Parkway

Entity Address, City or Town Parsippany

Entity Address, State or Province NJ Entity Address, Postal Zip Code 07054 City Area Code (855)Local Phone Number 776-6419 Written Communications false **Soliciting Material** false Pre-commencement Tender Offer false Pre-commencement Issuer Tender Offer false **Entity Emerging Growth Company** false

Entity Information, Former Legal or Registered Name Not Applicable

```
"lebellish": (
"lesal": (
"lesal": (
                                          |-
|
|
| "lenal": |
| "ideg-2010031_per.eni"
                               "nobean": [
"local": [
"ideg-2020031.and"
The state of the s
                               "Seminary "American Delication of the Control of th
                                                     "Band" "Summing Line",
"Bandshift" "Summing Line",
"Bandshift" "Transidil-100-111-0121-01-11",
"Sizes" t ware,
                     The state of the s
                               "Tanks off; |
"Tanks" |
"T
                                          The state of the state of the state of the second report containing salited financial channels, "Second state of the second report containing salited financial channels," Second state of the second 
                                          "Security of the Communication of the Communication
                                                     ]

"Londines": "Correct Fixed Trac Endints",
"Londines": "Correct Fixed Trac Endints",
"Londines": "Londines Londines Londines Londines
"Londines Londines Londines Londines Londines
"Londines Londines 
                                                               "Tang"; [
"Tang"; [
"Tang"; [
"Tang"; ]
"Sang"; [
"Sang"; ]
"Sang"; [
"Sang"; ]
"Sangmaniation"; "Business Elag that in true only for a form used as an annual report.";
"Sangmaniation"; "Business Elag that in true only for a form used as an annual report.";
"Salant"; "Shownman Elamani Empany"
                                          The second secon
                                                               "Seal Same", "Showmen' Friend Date Froms",
"Seal Same", "Showmen' Friend Date Froms",
"Seal Same", "Showmen' Friend Date Froms",
"Shappy, 'Shappy, many sale Ormes"
"Shappy, 'Shappy, many sale Ormes
"Shappy, 'Shappy, 'Shapp
```

), "localname": "DocumentPeriodEndDate", "nessi": "bttp://akel.eer.gov/dei/2021",

```
Target | Tar
"Tailor"; [
"Tearph"; [
"Tearph"; [
"Tearph"; [
"Tearph"; [
"Tearph"; [
"Monomonitation", "Rootene Eleg than in twee for a Shell Company Report pursuant to mention I3 or 11(4) of the Each
"Administration Commons Itali Company Report".
               The second secon
| Tanainam's Tanamania lanespara milipide foresent Tankilande",
Tanainam's Tanainam's lanespara milipide foresent Tankilande",
Tanainam's Tanainam's lanespara milipide foresent Tankilande",
Tanainam's Tanainam's lanespara
Tanainam
                                       Nerva's |
"esle": |
"decumentation": "Address Line I much as Atto, Building Hame, Etcent Esse"
"Label": "Entity Address, Address Line Coo"
       | Translater", "Entityladdrenskladers klast",
"manish", "bakyd/skai.ner.gev/des/2021",
"bakyd
                                       terma": [
"oule": [
"discussibilities Line 2 such as Street or Suite number",
"label": "Entity Address, Address Line Two",
Juniorania Thirty platementation visited 7, 2 marsh 7, 
                                       erun": |
"mil": |
"dommentation": "Hame of the City or Trun",
"label": "Entity Eddemo, City or Trun",
"Seminary "Seminary Carpitalism",
"Seminary "Seminary",
"Seminary",
"Seminary",
"Seminary",
"Seminary",
"Seminary",
"Seminary,",
"Semi
Section 2015 - Sectio
"Manial asse", "Manial pladement and an electric various",
"manel", "Manial pladement and an electric various",
"manel", "Manial pladement and electric various",
"manel and electric various ele
       |-
| "Records |
| "Records |
| "Assist" |
| Managementation" "The registrants involved in landscaping per
| Managementation" "The registrants involved in landscaping parties
| Assistant's "Entity Bankesping Proceedings, Reporting Correct"
| Lands" | "Entity Bankesping Proceedings, Reporting Correct"
               ];
"Lecalcome", "SchilySteckropt-yDrucendingeDeportingCorenot",
"wrwis": "bidgs//shel.em.ger(dei/2022",
"presentation";
"http://shenropsor.om/sole/Coren"
               Figure (
Street )
Street (
Str
```

"invaluame": "EntityCurrentEsportingDistur",
"neuri": "http://akel.ess.gov/dei/2021",

```
"sign" |
"seart" |
"seart"
        "Securiose", "Maisyful mensis of Parist's
"mass", "Maisyful mensis of Parist's
"mass", "Maisyful mensis of Parist's
"mass", "Maisyful mensis of Parist's
"mass', "Maisyman mensis of Parist's
"mass's

        Construction of the constr
"morus": |
"esia": |
"decummation": "Tramer Legal or Registered Hame of an entity",
"label": "Entity Information, Former Legal or Registered Hame"
lo"
"Annug": {
"Resum": {
"Resum": {
"Sele": {
"Sele": {
"Indecementation": THenless Else that is true when the
"label": "Edity Interactive Data Current"
                        Semination of Ministry Community of Semination of Seminati
        The state of the same one of the unity filing the oppose on quantitation in advance, which is expired by force filing the supers on quantitation in advance, which is expired by force filing the supers on quantitation in advance, which is expired by force filing the supers of quantitative filing the supers of qu
                "State" |
"State | | |
"State | | |
"State |
        ""sealoss", "EnthylbellCompany",
"level", "Behapi/Sell.com, operior/2021",
"behapi/Sell.com, operio
                        The state of the s
        The state of the s
                                        "sorus": |
"sole": |
"documentation": "Estension number for local phone number.",
"label": "Estension"
                | Translator's "Enteracion",
    "Secolianor's "Enteracion",

                                                aug": {
| terms": {
| Tesle": {
| Tesle": Tesle | Tesle | Those marker for entity.",
| Tabel": Timel Phose Norker
        The second of th
```

```
'Pands of S. |

'Engel' |

'Engel' |

'Annual |

'Annual S. |

'Annual S
                                                             "Institute": "Professionersonshipmines (Institute )
"Institute": "Professionersonshipmines (Institute )
"Professionersonshipmines (Inst
                                                                                      "Securioss", "Securios/2024kls",
"securioss", "Securios/2024kls",
"securios", "Setyp!/skal.com.gec/des/2021",
"Securioss", "Securios/2021/2022",
"Securioss", "securios/2021/2022",
"Securiosy", "securios/2021/2022",
"Securiosy", "securios/2021/2022",
"Securiosy", "securios/2021/2022",
"Securiosy", "securios/2021/2022",
"Securiosy", "securiosy
                                                             "Tennisma": "Tennishyfashaspilam",
"Sanish": "Mayor/skai.ver.qev/des/202",
"Sanish": "Mayor/skai.ver.qev/des/202",
"Sanishy'/skai.gam...mad.min/skei."
"Sanishy'm": "Maga.fashaspil-deliver")
"Sanishy'm": "Maga.fashaspil-deliveryym"
"Sanishy'm": "Sanishym's mightigashism": [
"Sanishym's "Sanishym's mightigashism": [
"Sanishym's "Sanishym's mightigashism": [
"Sanishym's "Sanishym's mightigashism": [
                                                                                      Transform (
"Thing," (
                                                 "Invaliant", "Security Supervision (Stilling in inst",
"Security Supervision (Stilling in inst",
"Parametriciant"),
"Balay (Initerpress - control of 10 Cores")
"Analogyer", "security Supervision (Stilling in institute Supervis
                                                                                      The Control of Control
                                                             Seminator * National application*, 
**Teach * Teach * 
                                     The second of th
The second secon
                        "Submension", "No-22"
"scil": [
"scil": [
"scil": [
"scil": [
"Submension", "Scil",
                        7, "615" (
"Mane": "Hamplishian S-T",
"Manher": "2327,
"Publisher": "2327,
"Publisher": "EET",
"Manelin": "600"

7, "Publisher": "EET",
"Manelin": "1207,
                                     "dis": [
"Hame": "Enoughten Act",
"Number": "Ention",
"Publisher": "EEC",
"Section": "12"
                        "Section": "12"
"12": [
"Same : "Exchange Jet",
"Somber": "260",
"Publisher": "EEC",
"Section": "12",
"Subtraction": "41-1"
                        "Subsension": "Ad-1"
"-2": [
"Ad": "Embangs Ast",
"Subsen": "Embangs Ast",
"Subsension": "Edd",
"Subsension": "Edd",
"Subsension": "Edd",
"Subsension": "Ad",
"Subsension": "Ad",
"Subsension": "Ad",
"Subsension": "Add",
"Subsension": "Add",
"Subsension": "Edd",
"Subsension": "Edd",
"Subsension": "Edd",
"Subsension": "TJ, IJ, IJs"
                        "Section": "12, 13, 15d

),

"67": {

"Esse": "Exchange Set",

"Sudder": "260",

"Publisher": "260",

"Section": "13e",

"Section": "40"

),
                        "Submemblant's "Gat"

"eff's "
"Star"s "Emphases John"
"Submem"s "Starburger John"
"Subh Labors"s "Starburger John"
"Subh Labors"s "Sub"
"Submission"s "Gat"
            "Schementian": "4"
);
"all": {
"blan": ["Kambange Jan"
"Spaker": "500";
"S
```